Business
Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older
Positive opinion from CHMP based on Phase 3 MARCH study with highly statistically significant
About this update from Mirum Pharmaceuticals, Inc.
[{"type":"text","content":"\n\nPositive opinion from CHMP based on Phase 3 MARCH study with highly statistically significant (p","length":139,"tagName":"div"}]